PreDxion Bio’s vision to bring precision medicine to the ICU will fundamentally change how we care for our sickest patients.

The Need

Since 1996, physicians have maintained a one-size-fits-all approach to treating immune dysfunction in the ICU: patients receive fluids, antibiotics, and blood pressure medication. This process is inefficient for hospitals and patients alike.

  • ICU admissions account for 1/3 of all hospital admissions, and there are over 5 million ICU admissions each year in the U.S. Approximately 80% of these admissions are due to underlying immune dysfunction, resulting in over 500,000 deaths annually.

  • ICU stays are expensive – these stays account for half of total aggregated hospital charges, or $81.7 billion.

  • Current technology requires 4-6 hours to determine the level of cytokines in a patient’s blood. For many patients, this period of time could be the difference between life and death.

PreDxion Bio is building a better way.

MicroKineTM was developed to measure a patient’s specific, individual immune response by identifying up to 6 cytokine proteins – proteins that control and direct the body’s response to inflammation – from a single drop of blood in just 30 minutes.

  • This quick turnaround time allows physicians to precisely treat patients before it is too late, thereby benefiting the patient.

  • The quick turnaround time also allows hospitals to treat patients more efficiently. This creates a costs savings opportunity, and increases the number of patients a given hospital can treat.